Surfactant Therapy - Neonatal Disorders

What is Surfactant Therapy?

Surfactant therapy involves administering exogenous surfactant to newborns, particularly preterm infants, who are suffering from Respiratory Distress Syndrome (RDS). This therapy helps reduce surface tension in the lungs, allowing them to remain expanded and thus improving oxygenation and ventilation.

Why is Surfactant Important?

Surfactant is a substance produced by the lungs that reduces surface tension within the alveoli. It is critical for maintaining lung stability and preventing alveolar collapse. In preterm infants, the production of surfactant is often insufficient, leading to RDS and other respiratory complications.

Who Needs Surfactant Therapy?

Surfactant therapy is primarily indicated for preterm infants with RDS. It may also be used in other conditions such as meconium aspiration syndrome, persistent pulmonary hypertension of the newborn (PPHN), and pneumonia, where lung function is compromised.

When is Surfactant Therapy Administered?

Early administration of surfactant, often within the first 2 hours of life, is recommended for infants at high risk of RDS. Prophylactic administration may be considered for extremely preterm infants (

Relevant Publications

Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study : Sleep-disordered breathing treatment in IPF.

Issue Release: 2024

Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort.

Issue Release: 2024

Curosurf surfactant application on preterm babies with respiratory complications-health-economic benefits.

Issue Release: 2024

Impact of Early Surfactant Administration on Ductus Arteriosus Assessed at 24 h in Preterm Neonates Less than 32 Weeks of Gestational Age.

Issue Release: 2024

The Synthetic Surfactant CHF5633 Restores Lung Function and Lung Architecture in Severe Acute Respiratory Distress Syndrome in Adult Rabbits.

Issue Release: 2024

Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.

Issue Release: 2024

The role of chest X-ray in the diagnosis of neonatal respiratory distress syndrome: a systematic review concerning low-resource birth scenarios.

Issue Release: 2024

Ultrasmall Inorganic Mesoporous Nanoparticles: Preparation, Functionalization and Application.

Issue Release: 2024

The Outcomes of Preterm Infants with Neonatal Respiratory Distress Syndrome Treated by Minimally Invasive Surfactant Therapy and Non-Invasive Ventilation.

Issue Release: 2024

Enhanced dissolution of amphotericin B through development of amorphous solid dispersions containing polymer and surfactants.

Issue Release: 2024

Quantitative Lung Ultrasonography to Guide Surfactant Therapy in Neonates Born Late Preterm and Later.

Issue Release: 2024

Fabrication of Rhenium Disulfide/Mesoporous Silica Core-Shell Nanoparticles for a pH-Responsive Drug Release and Combined Chemo-Photothermal Therapy.

Issue Release: 2024

Postexchange transfusion-related acute lung injury in a term neonate.

Issue Release: 2024

Microbubble-laden aerosols improve post-nasal aerosol penetration efficiency in a preterm neonate model.

Issue Release: 2024

The Role of Pulmonary Collectins, Surfactant Protein A (SP-A) and Surfactant Protein D (SP-D) in Cancer.

Issue Release: 2024

Poor prognostic factors for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies after combination therapy.

Issue Release: 2024

Influence of catheter thickness on respiratory physiology during less invasive surfactant administration in extremely preterm infants.

Issue Release: 2024

Oxidative stress, redox status and surfactant metabolism in mechanically ventilated patients receiving different approaches to oxygen therapy (MecROX): An observational study protocol for mechanistic evaluation.

Issue Release: 2024

Comparative Biophysical Study of Clinical Surfactants using Constrained Drop Surfactometry.

Issue Release: 2024

The association between serum 25-hydroxyvitamin D levels and retinopathy of prematurity in preterm infants.

Issue Release: 2024

How Can Integrative Approaches Benefit Pediatric Patients?

How to Use Temperature Sensors Correctly?

How does early intervention benefit children with emotional concerns?

What are the Common Causes of Pain in Neonates?

How does physical activity impact respiratory health?

What is Identity Formation?

Are There Any Research Advancements in XLA?

What are Community-Based Programs in Pediatrics?

How is Post-Transplant Care Managed?

What is Quadruple Therapy?

Partnered Content Networks

Relevant Topics